Neue Erkenntnisse aus der Leitlinie „Hepatozelluläres Karzinom“

Schlüsselwörter

Diagnostik - HCC - Leitlinie - Risikofaktoren - Therapien

Keywords

diagnostics - guideline - HCC - risk factors - therapies

• Literatur

• 1 Ascha MS, Hanouneh IA, Lopez R et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51: 1972-1978
• 2 Bruix J, Sherman M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022
• 3 Donadon V, Balbi M, Mas MD et al. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int 2010; 30: 750-758
• 4 Greten TF, Malek NP, Schmidt S et al. Diagnosis of and therapy for hepatocellular carcinoma. Z Gastroenterol 2013; 51: 1269-1326
• 5 Hassan MM, Hwang LY, Hatten CJ et al. Risk factors for hepato cellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002; 36: 1206-1213
• 6 Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90
• 7 Khalili K et al. Optimization of imaging diagnosis of 1-2 cm hepatocellular carcinoma: an analysis of diagnostic performance and resource utilization. J Hepatol 2011; 54: 723-728
• 8 Llovet JM et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-1739
• 9 Müllhaupt B, Durand F, Roskams T et al. Is tumor biopsy necessary?. Liver Transpl 2011; 17 (Suppl. 02) 14-25
• 10 Orlando A et al. Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol 2009; 104: 514-524
• 11 Seitz K. Quality of abdominal ultrasound. Ultraschall Med 2006; 27: 217-219
• 12 Sheu JC, Sung JL, Chen DS et al. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology 1985; 89: 259-266
• 13 Wittekind CH, Meyer HJ. TNM Klassifikation maligner Tumoren. 7.. Auflage Weinheim.: Wiley-VCH; 2010
• 14 Yeo W et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005; 97: 1532-1538
• 15 Yuen MF et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 2009; 50: 80-88